US10314809B2 - Application of derivative of clostridium ghonii - Google Patents

Application of derivative of clostridium ghonii Download PDF

Info

Publication number
US10314809B2
US10314809B2 US15/525,046 US201515525046A US10314809B2 US 10314809 B2 US10314809 B2 US 10314809B2 US 201515525046 A US201515525046 A US 201515525046A US 10314809 B2 US10314809 B2 US 10314809B2
Authority
US
United States
Prior art keywords
dcg
hncv
tumor
docetaxel
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active, expires
Application number
US15/525,046
Other versions
US20170354633A1 (en
Inventor
Laitian XING
Yong Wang
Mingqian WEI
Yanqiu XING
Lianlian LI
Lichao XING
Guangxia DENG
Hong Meng
Tao Huang
Dongxia YANG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SHIHUIDA PHARMACEUTICAL GROUP (JILIN) CO Ltd
Original Assignee
Shandong Xinchuang Biotechnology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shandong Xinchuang Biotechnology Co Ltd filed Critical Shandong Xinchuang Biotechnology Co Ltd
Assigned to SHANDONG XINCHUANG BIOTECHNOLOGY CO., LTD. reassignment SHANDONG XINCHUANG BIOTECHNOLOGY CO., LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: DENG, Guangxia, HUANG, TAO, LI, Lianlian, MENG, HONG, WANG, YONG, WEI, Mingqian, XING, Laitian, XING, Lichao, XING, Yanqiu, YANG, Dongxia
Publication of US20170354633A1 publication Critical patent/US20170354633A1/en
Application granted granted Critical
Publication of US10314809B2 publication Critical patent/US10314809B2/en
Assigned to SHIHUIDA PHARMACEUTICAL GROUP (JILIN) CO., LTD. reassignment SHIHUIDA PHARMACEUTICAL GROUP (JILIN) CO., LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: SHANDONG XINCHUANG BIOLOGICAL TECHNOLOGY CO., LTD
Active legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the invention relates to application of Derivatives of Clostridium ghonii (DCG), and in particular relates to application of DCG in preparation of medicines for treating non-small cell lung carcinoma (NSCLC), belonging to the technical field of biomedicines.
  • DCG Clostridium ghonii
  • NSCLC non-small cell lung carcinoma
  • the center areas of the solid tumors are characterized by increased interstitial pressure, lowered cell pH, low oxygen content and tumor cell heterogeneity.
  • the tumor microenvironments are also an important reason for tumor metastasis, invasion and insensitivity to conventional radiotherapy and chemotherapy.
  • the solid tumors contain hypoxic or necrotic areas, the hypoxic areas are far away from the blood vessels and are not rich in blood supply, and high interstitial pressure exists in the tumor centers, so that the tumor cells in the hypoxic areas difficulty obtain effective medicine concentration, and thus the hypoxic areas cannot be effectively treated by the conventional chemotherapy.
  • radiotherapy relies on the formation of oxygen free radicals, resulting in DNA damage in mitotic cells, so the lack of the oxygen free radicals in the tumor centers reduces the DNA damage during processing.
  • most chemotherapeutic medicines are effective only for rapid dividing tumor cells, and have poor efficacy in hypoxic tumor cells, stromal cells, and tumor tissue structures that have ceased to divide (fibronectin and collagen).
  • the conventional radiotherapy and chemotherapy often lack specific effects on tumor cells.
  • the tumor anaerobic microenvironments limit the efficacy of the conventional radiotherapy and chemotherapy as well as viral therapy, but provide a good opportunity for anaerobic bacteria to grow and play oncolysis effects in the hypoxic areas of the tumors.
  • DCG is obligate anaerobe Gram-positive bacillus, which has two growth states: spore and vegetative states.
  • DCG spores are very weak in antigen property, and can be used as a preparation for intravenous injection to reduce the organism stimulation.
  • the DCG spores in the blood can easily enter the tumor tissues, and germinate, reproduce, and secret lipase, protease and other hydrolases in the tumor hypoxic/necrotic areas to effectively and indiscriminately destroy various cells (tumor cells, non-cancerous interstitial cells, active dividing cells, stem cells or resting cells, etc.) and tumor structures (fibronectin and collagen) in the tumor tissue, causing oncolytic necrosis of the most of the tumors and achieving all the parenchyma and interstitial digestion of the tumors.
  • the tumor microenvironments are destroyed and altered fundamentally.
  • the destroying of the tumor microenvironments effectively restrains or reverses the tumor growth and destroys the tumor-forming condition, and even leads to the almost complete destroying and disappearance of the whole tumors, thereby being possible for NSCLC deep processing.
  • the hydrolases secreted by DCG dissolve tumor tissue-induced inflammatory response and directly involve in the destroying of reactive oxygen species, protease and other degrading enzymes on the tumor cells. More importantly, the inflammatory response can stimulate the organism to produce a strong cellular immune response, and destroy the residual tumor cell microenvironments.
  • Cipheral Patent CN103374538A (Application No. 201210310374.4) discloses a derivative bacterial strain of avirulent and non-pathogenic Clostridium ghonii , which is capable of inhibiting the growth of one or more solid tumors, and reversing or destroying one or more solid tumors.
  • CN103374538A also relates to a composition of derivative bacterial strain, targeting the dissolution of the solid tumors.
  • the invention provides application of a Derivatives of Clostridium ghonii MW-DCG-HNCv-18 strain, especially in the application of the preparation of medicines for treating non-small cell lung carcinoma.
  • Clostridium ghonii MW-DCG-HNCv-18 strain has white colonies on a reinforced clostridial-agar medium, is rounded, about 1-2 mm in diameter and slightly sticky, and has rough edges and consistent sizes.
  • the vegetative mass is singly growing short stem straight cells, and the thalli are 0.3-1.5 ⁇ m in width and 8-16 ⁇ m in length, and are Gram-positive.
  • the spores are located near the end of the thalli and are oval.
  • the strain is known and is available from the National Measurement Institute (Australia), with strain collection number of V12/001485.
  • a medicine for treating non-small cell lung carcinoma comprises a pharmaceutical composition prepared from the Derivatives of Clostridium ghonii MW-DCG-HNCv-18 strain and Docetaxel as active ingredients as well as pharmaceutically acceptable excipients.
  • the ratio of the Derivatives of Clostridium ghonii MW-DCG-HNCv-18 strain spores to Docetaxel is that per mg of Docetaxel is combined with 5 ⁇ 10 6 -3.0 ⁇ 10 7 strain spores.
  • the ratio of the Derivatives of Clostridium ghonii MW-DCG-HNCv-18 strain spores to Docetaxel is that per mg of Docetaxel is combined with 1.0 ⁇ 10 7 -2.0 ⁇ 10 7 strain spores.
  • the ratio of the Derivatives of Clostridium ghonii MW-DCG-HNCv-18 strain spores to Docetaxel is that per mg of Docetaxel is combined with 1.5 ⁇ 10 7 strain spores.
  • the dosage form of the medicine for treating non-small cell lung carcinoma is spore freeze-dried powder for injection.
  • the spore freeze-dried powder for injection can be prepared by a low-temperature freeze-drying technology.
  • the spore freeze-dried powder for injection is mixed with a solvent for use, wherein the solvent is selected from Ringer's solution, saline with mass concentration of 0.9%, and phosphate buffer.
  • the solvent is required to meet the requirements of nontoxicity and injectability.
  • the medicine is administrated through intravenous, spinal, intramuscular, subcutaneous, intratumoral injection and intraperitoneal manners.
  • FIG. 1 is a picture of the anti-tumor effect of MW-DCG-HNCv-18 in Example 1;
  • FIG. 2 is tumor growth curves of various test groups obtained by testing in Example 2;
  • FIG. 3 is a result picture of the anti-tumor effect at 20th day in testing in Example 2.
  • the MW-DCG-HNCv-18 strain is from the National Measurement Institute (Australia), with strain collection number of V12/001485.
  • the MW-DCG-LCv-26 strain is from the National Measurement Institute (Australia), with strain collection number of V12/001486.
  • the MW-DCG-CCv-17 strain is from the National Measurement Institute (Australia), with strain collection number of V12/001487.
  • Clostridium novyi -NT strain is from ATCC, with strain collection number of ATCC®7659TM.
  • Cetuximab (5 mg/ml) is purchased from Germany MERCK Serono, with production lot number: 132393, and production date: February 2013.
  • Docetaxel is purchased from Qilu Pharmaceutical Co., Ltd., with production lot number: 3030062TA, and production date: Mar. 18, 2013.
  • Adriacin is purchased from Shenzhen Wanle Pharmaceutical Co., Ltd., with production lot number
  • the non-small cell lung carcinoma A549 cells were injected into the subcutaneous positions at femoral lateral parts of right backs of female Balb/c-nu/nu nude mice (5 weeks old, 20 g) by subcutaneous injection.
  • the in-vivo anti-tumor test was performed when the tumor volume was 300 mm 3 .
  • the major diameter (a) and transverse diameter (b) of the transplanted tumors of the nude mice were measured with a vernier caliper, 3 to 4 times a week.
  • the general situations of tumor-bearing mice, including body weight, feeding, drinking, mental state, behavior, fur color, excretion and death were observed and recorded.
  • Tumor inhibition rate (%) (average tumor weight in the control group ⁇ average tumor weight in the test group)/average tumor weight in the control group ⁇ 100%.
  • Tumor necrosis rate (%) cross-sectional area of the necrotic area/cross-sectional area of the entire tumor ⁇ 100%.
  • Tumor oncolysis rate (%) number of animals undergoing tumor oncolysis/total number of animals in this group ⁇ 100%.
  • the overall survival time of tumor-bearing mice the nude mice in each group after processing were fed until natural death, and the survival time was calculated.
  • the MW-DCG-HNCv-18 has tumor inhibition rate, necrosis rate and oncolysis rate to the NSCLC tumor-bearing mice model of 51.1%, 76.55% and 100%, respectively, which are significantly higher than those of the MW-DCG-LCv-26 strain and MW-DCG-CCv-17 strain.
  • the MW-DCG-HNCv-18 strain has higher tumor inhibition rate, necrosis rate and oncolysis rate, but the difference was not significant.
  • the MW-DCG-HNCv-18 strain prolongs the mean survival days of the tumor-bearing mice compared with the MW-DCG-LCv-26, MW-DCG-CCv-17 and C. novyi -NT strains, and the mean survival days are significantly longer than those of the tumor-bearing mice in the C. novyi -NT group.
  • the studies find that the body weight of the tumor-bearing mice in the C. novyi -NT group decreases, while the body weight of the tumor-bearing mice in the other three groups does not change.
  • MW-DCG-HNCv-18 strain shows good effectiveness and safety compared with the MW-DCG-LCv-26, MW-DCG-CCv-17 and C. novyi -NT strains.
  • the non-small cell lung carcinoma A549 cells were injected into the subcutaneous positions at femoral lateral parts of right backs of female Balb/c-nu/nu nude mice (5 weeks old, 20 g) by subcutaneous injection.
  • the in-vivo test was performed when the tumor volume was 300 mm 3 .
  • n 15, spores were intravenously injected to the tails, and the dose was 3 ⁇ 10 8 /(kg ⁇ body weight).
  • Docetaxel was intravenously injected to the tails on the 4th day and 11th day, and the dose was 20 mg/(kg ⁇ body weight).
  • the major diameter (a) and transverse diameter (b) of the transplanted tumors of the nude mice were measured with a vernier caliper, 3 to 4 times a week, the tumor volume of each group was calculated, and the anti-tumor effects of the strains were observed dynamically. At the same time, the body weight, feeding, drinking, mental state, behavior, fur color, excretion and death situations of the tumor-bearing mice were observed and recorded.
  • Tumor inhibition rate (%) (average tumor weight in the control group ⁇ average tumor weight in the test group)/average tumor weight in the control group ⁇ 100%.
  • Tumor necrosis rate (%) area of the necrotic area/area of the entire tumor ⁇ 100%.
  • Cure rate (%) number of animals with tumor completely removed/total number of animals in this group ⁇ 100%.
  • the overall survival time of the tumor-bearing mice the nude mice in each group after processing were fed until natural death, and the survival time was calculated.
  • Tumor inhibition Necrosis mean survival Group rate rate Cure rate days Control group 0 0 0% 24.4 day
  • the MW-DCG-HNCv-18+Docetaxel group has significantly higher tumor inhibition rate and necrosis rate to the non-small cell lung carcinoma tumor-bearing mice model than other combined administration groups.
  • the tumor volumes of the tumor-bearing mice in the MW-DCG-HNCv-18+Docetaxel group are inhibited from the 6th day after administration, and are always kept at about 300 mm 3 , while the tumor volumes of the tumor-bearing mice in the other groups increase to different extents ( FIG. 2 ).
  • the tumors of 26.7% of the tumor-bearing mice in the MW-DCG-HNCv-18+Docetaxel group are almost completely removed ( FIG. 1 ), regarding as cure, and the cure rate is significantly higher than that of the other three combined administration groups.
  • the MW-DCG-HNCv-18+Docetaxel group prolongs the survival days of the tumor-bearing mice to 71.0 days, which are 2.9 times those of the tumor-bearing mice in the control group, and are significantly longer than those of the MW-DCG-HNCv-18+Cetuximab group, the MW-DCG-HNCv-18+Adriacin group and the C. novyi -NT+Docetaxel group. It is found that the MW-DCG-HNCv-18 in combination Docetaxel for treatment of the non-small cell lung carcinoma shows super-superposition effects.
  • the non-small cell lung carcinoma A549 cells were injected into the subcutaneous positions at femoral lateral parts of right backs of female Balb/c-nu/nu nude mice (5 weeks old, 20 g) by subcutaneous injection.
  • the in-vivo test was performed when the tumor volume was 300 mm 3 .
  • the major diameter (a) and transverse diameter (b) of the transplanted tumors of the nude mice were measured with a vernier caliper, 3 to 4 times a week. At the same time, the body weight, feeding, drinking, mental state, behavior, fur color, excretion and death situations of the tumor-bearing mice were observed and recorded.
  • Tumor inhibition rate (%) (average tumor weight in the control group ⁇ average tumor weight in the test group)/average tumor weight in the control group ⁇ 100%.
  • Tumor necrosis rate (%) cross-sectional area of the necrotic area/cross-sectional area of the entire tumor ⁇ 100%.
  • Cure rate (%) number of animals with tumor completely removed/total number of animals in this group ⁇ 100%.
  • the overall survival time of the tumor-bearing mice the nude mice in each group after processing were fed until natural death, and the survival time was calculated.
  • the tumor inhibition rate, necrosis rate, cure rate and mean survival days of the MW-DCG-HNCv-18 spore+Docetaxel-1 group are significantly lower than those of other MW-DCG-HNCv-18 spore+Docetaxel groups.
  • MW-DCG-HNCv-18 spore+Docetaxel-2 group MW-DCG-HNCv-18 spore+Docetaxel-3 group and MW-DCG-HNCv-18 spores+Docetaxel-4 group
  • the tumor inhibition rate, necrosis rate, cure rate and mean survival days gradually increase, and the anti-tumor effect of the MW-DCG-HNCv-18 spore+Docetaxel-4 group is the best.
  • the MW-DCG-HNCv-18 spore+Docetaxel-7 group is not significantly different in the tumor inhibition rate and necrosis rate, but significantly lower in the cure rate and mean survival days.
  • the preferred range of the MW-DCG-HNCv-18 spores in combination with Docetaxel for the treatment of non-small cell lung carcinoma should be 1.0 ⁇ 10 8 -6.0 ⁇ 10 8 /(kg ⁇ body weight), and the most preferred dose is 3.0 ⁇ 10 8 cells/(kg ⁇ body weight).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Application of Derivatives of Clostridium ghonii, especially in the application of Derivatives of Clostridium ghonii MW-DCG-HNCv-18 in preparation of medicines for treating non-small cell lung carcinoma. It also discloses a medicine combining the Derivatives of Clostridium ghonii MW-DCG-HNCv-18 strain with Docetaxel as the active ingredients. According to the invention, the MW-DCG-HNCv-18 strain is found to have specific inhibition effect on non-small cell lung carcinoma for the first time, the inhibition effect on the non-small cell lung carcinoma is significantly superior to that of other known similar strains, and through screening, the MW-DCG-HNCv-18 strain is found to have more prominent inhibition effect on non-small cell lung carcinoma when combined with Docetaxel injection.

Description

This application is the U.S. national phase of International Application No. number PCT/CN2015/083573 filed on 8 Jul. 2015 which designated the U.S. and claims priority to Chinese Application Nos. filed CN 201410803072.X filed on 19 Dec. 2014, the entire contents of each of which are hereby incorporated by reference.
TECHNICAL FIELD
The invention relates to application of Derivatives of Clostridium ghonii (DCG), and in particular relates to application of DCG in preparation of medicines for treating non-small cell lung carcinoma (NSCLC), belonging to the technical field of biomedicines.
BACKGROUND TECHNOLOGY
At present, the understanding of pathophysiology of solid tumors is increasingly turning to their unique growth microenvironments. The center areas of the solid tumors are characterized by increased interstitial pressure, lowered cell pH, low oxygen content and tumor cell heterogeneity. The tumor microenvironments are also an important reason for tumor metastasis, invasion and insensitivity to conventional radiotherapy and chemotherapy. First, the solid tumors contain hypoxic or necrotic areas, the hypoxic areas are far away from the blood vessels and are not rich in blood supply, and high interstitial pressure exists in the tumor centers, so that the tumor cells in the hypoxic areas difficulty obtain effective medicine concentration, and thus the hypoxic areas cannot be effectively treated by the conventional chemotherapy. Second, radiotherapy relies on the formation of oxygen free radicals, resulting in DNA damage in mitotic cells, so the lack of the oxygen free radicals in the tumor centers reduces the DNA damage during processing. Third, most chemotherapeutic medicines are effective only for rapid dividing tumor cells, and have poor efficacy in hypoxic tumor cells, stromal cells, and tumor tissue structures that have ceased to divide (fibronectin and collagen). Moreover, the conventional radiotherapy and chemotherapy often lack specific effects on tumor cells. The tumor anaerobic microenvironments limit the efficacy of the conventional radiotherapy and chemotherapy as well as viral therapy, but provide a good opportunity for anaerobic bacteria to grow and play oncolysis effects in the hypoxic areas of the tumors.
DCG is obligate anaerobe Gram-positive bacillus, which has two growth states: spore and vegetative states. DCG spores are very weak in antigen property, and can be used as a preparation for intravenous injection to reduce the organism stimulation. Due to disordered vascular tissue structures of the tumors, the DCG spores in the blood can easily enter the tumor tissues, and germinate, reproduce, and secret lipase, protease and other hydrolases in the tumor hypoxic/necrotic areas to effectively and indiscriminately destroy various cells (tumor cells, non-cancerous interstitial cells, active dividing cells, stem cells or resting cells, etc.) and tumor structures (fibronectin and collagen) in the tumor tissue, causing oncolytic necrosis of the most of the tumors and achieving all the parenchyma and interstitial digestion of the tumors. The tumor microenvironments are destroyed and altered fundamentally. The destroying of the tumor microenvironments effectively restrains or reverses the tumor growth and destroys the tumor-forming condition, and even leads to the almost complete destroying and disappearance of the whole tumors, thereby being possible for NSCLC deep processing. The hydrolases secreted by DCG dissolve tumor tissue-induced inflammatory response and directly involve in the destroying of reactive oxygen species, protease and other degrading enzymes on the tumor cells. More importantly, the inflammatory response can stimulate the organism to produce a strong cellular immune response, and destroy the residual tumor cell microenvironments.
Chinese Patent CN103374538A (Application No. 201210310374.4) discloses a derivative bacterial strain of avirulent and non-pathogenic Clostridium ghonii, which is capable of inhibiting the growth of one or more solid tumors, and reversing or destroying one or more solid tumors. CN103374538A also relates to a composition of derivative bacterial strain, targeting the dissolution of the solid tumors.
However, due to the different formation reasons of the solid tumors, the effects of different strains on the solid tumors are specific. Therefore, further study on the specific effects of different strains on different solid tumors has become a hotspot in this field.
SUMMARY OF THE INVENTION
Aiming at the shortcomings of the existing technology, the invention provides application of a Derivatives of Clostridium ghonii MW-DCG-HNCv-18 strain, especially in the application of the preparation of medicines for treating non-small cell lung carcinoma.
The Derivatives of Clostridium ghonii MW-DCG-HNCv-18 strain has white colonies on a reinforced clostridial-agar medium, is rounded, about 1-2 mm in diameter and slightly sticky, and has rough edges and consistent sizes. The vegetative mass is singly growing short stem straight cells, and the thalli are 0.3-1.5 μm in width and 8-16 μm in length, and are Gram-positive. The spores are located near the end of the thalli and are oval. The strain is known and is available from the National Measurement Institute (Australia), with strain collection number of V12/001485.
A medicine for treating non-small cell lung carcinoma comprises a pharmaceutical composition prepared from the Derivatives of Clostridium ghonii MW-DCG-HNCv-18 strain and Docetaxel as active ingredients as well as pharmaceutically acceptable excipients.
According to a preferred embodiment of the invention, the ratio of the Derivatives of Clostridium ghonii MW-DCG-HNCv-18 strain spores to Docetaxel is that per mg of Docetaxel is combined with 5×106-3.0×107 strain spores.
According to a further preferred embodiment of the invention, the ratio of the Derivatives of Clostridium ghonii MW-DCG-HNCv-18 strain spores to Docetaxel is that per mg of Docetaxel is combined with 1.0×107-2.0×107 strain spores.
According to a more preferred embodiment of the invention, the ratio of the Derivatives of Clostridium ghonii MW-DCG-HNCv-18 strain spores to Docetaxel is that per mg of Docetaxel is combined with 1.5×107 strain spores.
According to a preferred embodiment of the invention, the dosage form of the medicine for treating non-small cell lung carcinoma is spore freeze-dried powder for injection.
The spore freeze-dried powder for injection can be prepared by a low-temperature freeze-drying technology.
According to a further preferred embodiment of the invention, the spore freeze-dried powder for injection is mixed with a solvent for use, wherein the solvent is selected from Ringer's solution, saline with mass concentration of 0.9%, and phosphate buffer. The solvent is required to meet the requirements of nontoxicity and injectability. The medicine is administrated through intravenous, spinal, intramuscular, subcutaneous, intratumoral injection and intraperitoneal manners.
Beneficial Effects
  • 1. The MW-DCG-HNCv-18 strain is found to have specific inhibition effect on non-small cell lung carcinoma for the first time in the invention, the inhibition effect on the non-small cell lung carcinoma is significantly superior to that of other known similar strains, and through screening, the MW-DCG-HNCv-18 strain is found to have more prominent inhibition effect on non-small cell lung carcinoma when combined with Docetaxel injection, so that a novel way is provided for the treatment of non-small cell lung carcinoma.
  • 2. The DCG spores of the invention have the characteristic of obligate anaerobic, and can move to the hypoxic areas of the tumors, causing oncolytic necrosis of the most of the tumors, when they reach the edges of oxygen-rich tumors, bacterial proliferation and movement stagnate, the residual tumor tissues at the edges still have potential for recurrence, and Docetaxel can kill the rapid dividing tumor cells in the oxygen-rich environment at the edges of the tumor tissues at lower doses. At the same time, chemotherapy medicines can also increase the degree of hypoxia in the tumors by destroying the blood vessels of the tumors, thereby being more conducive to DCG colonization and improving oncolytic effect. The DCG spores and the chemotherapy medicines synergistically form a tumor-targeting three-dimensional and highly-targeted oncolytic effect to achieve complementary advantages, both inside and outside attack, and “super-superposition effect”.
DRAWING DESCRIPTION
FIG. 1 is a picture of the anti-tumor effect of MW-DCG-HNCv-18 in Example 1;
FIG. 2 is tumor growth curves of various test groups obtained by testing in Example 2;
FIG. 3 is a result picture of the anti-tumor effect at 20th day in testing in Example 2.
 EMBODIMENTS
The invention will be further described with reference to the following examples, but the scope of the invention is not limited thereto.
Source of Strain
The MW-DCG-HNCv-18 strain is from the National Measurement Institute (Australia), with strain collection number of V12/001485.
The MW-DCG-LCv-26 strain is from the National Measurement Institute (Australia), with strain collection number of V12/001486.
The MW-DCG-CCv-17 strain is from the National Measurement Institute (Australia), with strain collection number of V12/001487.
The Clostridium novyi-NT strain is from ATCC, with strain collection number of ATCC®7659™.
Cetuximab (5 mg/ml) is purchased from Germany MERCK Serono, with production lot number: 132393, and production date: February 2013.
Docetaxel is purchased from Qilu Pharmaceutical Co., Ltd., with production lot number: 3030062TA, and production date: Mar. 18, 2013.
Adriacin is purchased from Shenzhen Wanle Pharmaceutical Co., Ltd., with production lot number|: 1206E4, and production date: April 2013.
Example 1
Study Method:
□Construction of Non-Small Cell Lung Carcinoma Models
The non-small cell lung carcinoma A549 cells were injected into the subcutaneous positions at femoral lateral parts of right backs of female Balb/c-nu/nu nude mice (5 weeks old, 20 g) by subcutaneous injection. The in-vivo anti-tumor test was performed when the tumor volume was 300 mm3.
{circle around (2)} Animal Grouping and Processing
Control group: n=15 (n is the number of animals in each group), and 0.2 ml of PBS buffer was intravenously injected to the tails;
MW-DCG-HNCv-18 spore group: n=15, spores were intravenously injected to the tails on the first day, and the dose was 3×108/(kg·body weight).
MW-DCG-LCv-26 spore group: n=15, spores were intravenously injected to the tails on the first day, and the dose was 3×108/(kg·body weight).
MW-DCG-CCv-17 spore group: n=15, spores were intravenously injected to the tails on the first day, and the dose was 3×108/(kg·body weight).
C. novyi-NT spore group: n=15, spores were intravenously injected to the tails on the first day, and the dose was 3×108/(kg·body weight).
{circle around (3)} Detection Index
The major diameter (a) and transverse diameter (b) of the transplanted tumors of the nude mice were measured with a vernier caliper, 3 to 4 times a week. At the same time, the general situations of tumor-bearing mice, including body weight, feeding, drinking, mental state, behavior, fur color, excretion and death were observed and recorded.
{circle around (4)} Evaluation Standard
The tumor volume (V=½×a×b2) was calculated according to the measured major diameter and transverse diameter data of the tumors, the curve was drawn and the tumors were observed dynamically.
Tumor inhibition rate (%)=(average tumor weight in the control group−average tumor weight in the test group)/average tumor weight in the control group×100%.
Tumor necrosis rate (%)=cross-sectional area of the necrotic area/cross-sectional area of the entire tumor×100%.
Tumor oncolysis rate (%)=number of animals undergoing tumor oncolysis/total number of animals in this group×100%.
The overall survival time of tumor-bearing mice: the nude mice in each group after processing were fed until natural death, and the survival time was calculated.
{circle around (5)} Result
Tumor
inhibition Necrosis Oncolysis Mean survival Toxicity
Group rate rate rate days level
Control group 0 0 0 25.0 day No
MW-DCG-HNCv-18 51.1% 76.55% 100% 45.8 day No
group
MW-DCG-LCv-26 39.3% 65.00% 68% 36.3 day No
group
MW-DCG-CCv-17 36.9% 59.27% 68% 34.5 day No
group
C. novyi-NT group 47.8% 71.42% 84% 32.0 day Yes (body
weight
decrease)
Consequently, (1) Effectiveness: compared with the MW-DCG-LCv-26 strain and MW-DCG-CCv-17 strain, the MW-DCG-HNCv-18 has tumor inhibition rate, necrosis rate and oncolysis rate to the NSCLC tumor-bearing mice model of 51.1%, 76.55% and 100%, respectively, which are significantly higher than those of the MW-DCG-LCv-26 strain and MW-DCG-CCv-17 strain. Compared with the C. novyi-NT strain, the MW-DCG-HNCv-18 strain has higher tumor inhibition rate, necrosis rate and oncolysis rate, but the difference was not significant. At the same time, the study results show that there is a large area of necrosis after the 35th day of spore injection in the MW-DCG-HNCv-18 spore group, while the tumor volume in the control group is continued to increase (FIG. 1).
(2) Safety: the MW-DCG-HNCv-18 strain prolongs the mean survival days of the tumor-bearing mice compared with the MW-DCG-LCv-26, MW-DCG-CCv-17 and C. novyi-NT strains, and the mean survival days are significantly longer than those of the tumor-bearing mice in the C. novyi-NT group. The studies find that the body weight of the tumor-bearing mice in the C. novyi-NT group decreases, while the body weight of the tumor-bearing mice in the other three groups does not change.
It is found that the MW-DCG-HNCv-18 strain shows good effectiveness and safety compared with the MW-DCG-LCv-26, MW-DCG-CCv-17 and C. novyi-NT strains.
Example 2
Study Method:
{circle around (1)} Construction of Non-Small Cell Lung Carcinoma Models
The non-small cell lung carcinoma A549 cells were injected into the subcutaneous positions at femoral lateral parts of right backs of female Balb/c-nu/nu nude mice (5 weeks old, 20 g) by subcutaneous injection. The in-vivo test was performed when the tumor volume was 300 mm3.
{circle around (2)} Animal Grouping and Processing
Control group: n=15, and 0.2 ml of PBS buffer was intravenously injected to the tails;
Docetaxel group: n=15, Docetaxel was intravenously injected to the tails on the 4th day and 11th day, the dose was 20 mg/(kg·body weight), and the application dose of Docetaxel was the optimal application dose.
MW-DCG-HNCv-18 spore group: n=15, spores were intravenously injected to the tails, and the dose was 3×108/(kg·body weight).
MW-DCG-HNCv-18 spore+Cetuximab group: n=15, MW-DCG-HNCv-18 spores were intravenously injected to the tails on the first day, and the dose was 3×108/(kg·body weight); Cetuximab was intravenously injected to the tails on the 4th day and 11th day, the dose was 70 mg/(kg·body weight), and the application dose of Cetuximab was the optimal application dose.
MW-DCG-HNCv-18 spore+Cetuximab group: n=15, MW-DCG-HNCv-18 spores were intravenously injected to the tails on the first day, and the dose was 3×108/(kg·body weight); Adriacin was intravenously injected to the tails on the 4th day and 11th day, the dose was 10 mg/(kg·body weight), and the application dose of Adriacin was the optimal application dose.
MW-DCG-HNCv-18 spore+Docetaxel group: n=15, MW-DCG-HNCv-18 spores were intravenously injected to the tails on the first day, and the dose was 3×108/(kg·body weight); Docetaxel was intravenously injected to the tails on the 4th day and 11th day, and the dose was 20 mg/(kg·body weight).
C. novyi-NT spore+Docetaxel group: n=15, C. novyi-NT spores were intravenously injected to the tails on the first day, and the dose was 3×108/(kg·body weight);
Docetaxel was intravenously injected to the tails on the 4th day and 11th day, and the dose was 20 mg/(kg·body weight).
{circle around (3)} Detection Index
The major diameter (a) and transverse diameter (b) of the transplanted tumors of the nude mice were measured with a vernier caliper, 3 to 4 times a week, the tumor volume of each group was calculated, and the anti-tumor effects of the strains were observed dynamically. At the same time, the body weight, feeding, drinking, mental state, behavior, fur color, excretion and death situations of the tumor-bearing mice were observed and recorded.
{circle around (4)} Evaluation Standard
The tumor volume (V=½×a×b2) was calculated according to the measured major diameter and transverse diameter data of the tumors, the curve was drawn and the tumors were observed dynamically.
Tumor inhibition rate (%)=(average tumor weight in the control group−average tumor weight in the test group)/average tumor weight in the control group×100%.
Tumor necrosis rate (%)=area of the necrotic area/area of the entire tumor×100%.
Cure rate (%)=number of animals with tumor completely removed/total number of animals in this group×100%.
The overall survival time of the tumor-bearing mice: the nude mice in each group after processing were fed until natural death, and the survival time was calculated.
␣Result
Tumor
inhibition Necrosis mean survival
Group rate rate Cure rate days
Control group
0 0 0% 24.4 day
Docetaxel group 55.9% 22.2 0% 35.5 day
MW-DCG-HNCv-18 group 51.4% 76.6 0% 43.8 day
MW-DCG-HNCv-18 + Cetuximab 59.9% 76.1% 13.3%   58.2 day
group
MW-DCG-HNCv-18 + Adriacin 57.7% 74.7% 0% 47.0 day
group
MW-DCG-HNCv-18 + Docetaxel 79.8% 91.2% 26.7%   71.0 day
group
C. novyi-NT + Docetaxel group 67.4% 78.6% 13.3%   53.6 day
Consequently, the MW-DCG-HNCv-18+Docetaxel group has significantly higher tumor inhibition rate and necrosis rate to the non-small cell lung carcinoma tumor-bearing mice model than other combined administration groups. The tumor volumes of the tumor-bearing mice in the MW-DCG-HNCv-18+Docetaxel group are inhibited from the 6th day after administration, and are always kept at about 300 mm3, while the tumor volumes of the tumor-bearing mice in the other groups increase to different extents (FIG. 2). At the same time, the tumors of 26.7% of the tumor-bearing mice in the MW-DCG-HNCv-18+Docetaxel group are almost completely removed (FIG. 1), regarding as cure, and the cure rate is significantly higher than that of the other three combined administration groups.
The MW-DCG-HNCv-18+Docetaxel group prolongs the survival days of the tumor-bearing mice to 71.0 days, which are 2.9 times those of the tumor-bearing mice in the control group, and are significantly longer than those of the MW-DCG-HNCv-18+Cetuximab group, the MW-DCG-HNCv-18+Adriacin group and the C. novyi-NT+Docetaxel group. It is found that the MW-DCG-HNCv-18 in combination Docetaxel for treatment of the non-small cell lung carcinoma shows super-superposition effects.
Example 3
Study Method:
{circle around (1)} Construction of Non-Small Cell Lung Carcinoma Models
The non-small cell lung carcinoma A549 cells were injected into the subcutaneous positions at femoral lateral parts of right backs of female Balb/c-nu/nu nude mice (5 weeks old, 20 g) by subcutaneous injection. The in-vivo test was performed when the tumor volume was 300 mm3.
{circle around (2)} Animal Grouping and Processing
Control group: n=15, and 0.2 ml of PBS buffer was intravenously injected to the tails;
MW-DCG-HNCv-18 spore+Docetaxel-1 group: n=15, MW-DCG-HNCv-18 spores were intravenously injected to the tails on the first day, and the dose was 0.5×108/(kg·body weight); Docetaxel was intravenously injected to the tails on the 4th day and 11th day, and the dose was 20 mg/(kg·body weight).
MW-DCG-HNCv-18 spore+Docetaxel-2 group: n=15, MW-DCG-HNCv-18 spores were intravenously injected to the tails on the first day, and the dose was 1.0×108/(kg·body weight); Docetaxel was intravenously injected to the tails on the 4th day and 11th day, and the dose was 20 mg/(kg·body weight).
MW-DCG-HNCv-18 spore+Docetaxel-3 group: n=15, MW-DCG-HNCv-18 spores were intravenously injected to the tails on the first day, and the dose was 2.0×108/(kg·body weight); Docetaxel was intravenously injected to the tails on the 4th day and 11th day, and the dose was 20 mg/(kg·body weight).
MW-DCG-HNCv-18 spore+Docetaxel-4 group: n=15, MW-DCG-HNCv-18 spores were intravenously injected to the tails on the first day, and the dose was 3.0×108/(kg·body weight); Docetaxel was intravenously injected to the tails on the 4th day and 11th day, and the dose was 20 mg/(kg·body weight).
MW-DCG-HNCv-18 spore+Docetaxel-5 group: n=15, MW-DCG-HNCv-18 spores were intravenously injected to the tails on the first day, and the dose was 5.0×108/(kg·body weight); Docetaxel was intravenously injected to the tails on the 4th day and 11th day, and the dose was 20 mg/(kg·body weight).
MW-DCG-HNCv-18 spore+Docetaxel-6 group: n=15, MW-DCG-HNCv-18 spores were intravenously injected to the tails on the first day, and the dose was 6.0×108/(kg·body weight); Docetaxel was intravenously injected to the tails on the 4th day and 11th day, and the dose was 20 mg/(kg·body weight).
MW-DCG-HNCv-18 spore+Docetaxel-7 group: n=15, MW-DCG-HNCv-18 spores were intravenously injected to the tails on the first day, and the dose was 7.0×108/(kg·body weight); Docetaxel was intravenously injected to the tails on the 4th day and 11th day, and the dose was 20 mg/(kg·body weight).
{circle around (3)} Detection Index
The major diameter (a) and transverse diameter (b) of the transplanted tumors of the nude mice were measured with a vernier caliper, 3 to 4 times a week. At the same time, the body weight, feeding, drinking, mental state, behavior, fur color, excretion and death situations of the tumor-bearing mice were observed and recorded.
{circle around (4)} Evaluation Standard
The tumor volume (V=½×a×b2) was calculated according to the measured major diameter and transverse diameter data of the tumors, the curve was drawn and the tumors were observed dynamically.
Tumor inhibition rate (%)=(average tumor weight in the control group−average tumor weight in the test group)/average tumor weight in the control group×100%.
Tumor necrosis rate (%)=cross-sectional area of the necrotic area/cross-sectional area of the entire tumor×100%.
Cure rate (%)=number of animals with tumor completely removed/total number of animals in this group×100%.
The overall survival time of the tumor-bearing mice: the nude mice in each group after processing were fed until natural death, and the survival time was calculated.
□Result
Tumor
inhibition Necrosis Cure mean survival
Group rate rate rate days
Control group
0 0 0 26.8 day
MW-DCG-HNCv-18 spore + Docetaxel-1 52.4% 44.4%   0% 41.2 day
group
MW-DCG-HNCv-18 spore + Docetaxel-2 64.2% 76.1%   0% 49.0 day
group
MW-DCG-HNCv-18 spore + Docetaxel-3 68.9% 80.2% 13.3% 56.0 day
group
MW-DCG-HNCv-18 spore + Docetaxel-4 79.7% 90.7% 26.7% 71.3 day
group
MW-DCG-HNCv-18 spore + Docetaxel-5 79.4% 84.6% 13.3% 66.4 day
group
MW-DCG-HNCv-18 spore + Docetaxel-6 79.1% 85.5% 13.3% 66.0 day
group
MW-DCG-HNCv-18 spore + Docetaxel-7 79.5% 87.9%   0% 54.7 day
group
According to the above results, the tumor inhibition rate, necrosis rate, cure rate and mean survival days of the MW-DCG-HNCv-18 spore+Docetaxel-1 group are significantly lower than those of other MW-DCG-HNCv-18 spore+Docetaxel groups.
In the MW-DCG-HNCv-18 spore+Docetaxel-2 group, MW-DCG-HNCv-18 spore+Docetaxel-3 group and MW-DCG-HNCv-18 spores+Docetaxel-4 group, with the increase of MW-DCG-HNCv-18 spore dose, the tumor inhibition rate, necrosis rate, cure rate and mean survival days gradually increase, and the anti-tumor effect of the MW-DCG-HNCv-18 spore+Docetaxel-4 group is the best.
Compared with the MW-DCG-HNCv-18 spore+Docetaxel-4 group, the MW-DCG-HNCv-18 spore+Docetaxel-7 group is not significantly different in the tumor inhibition rate and necrosis rate, but significantly lower in the cure rate and mean survival days.
Considering the production cost of the MW-DCG-HNCv-18 spores, it is considered that the preferred range of the MW-DCG-HNCv-18 spores in combination with Docetaxel for the treatment of non-small cell lung carcinoma should be 1.0×108-6.0×108/(kg·body weight), and the most preferred dose is 3.0×108 cells/(kg·body weight).

Claims (5)

What is claimed is:
1. A pharmaceutical composition for treating non-small cell lung carcinoma, wherein the pharmaceutical composition includes Clostridium ghonii MW-DCG-HNCv-18 deposited at the National Measurement Institute (NMI) under NMI accession number V12/001485, Docetaxel, and pharmaceutically acceptable excipients; the ratio of spores of Clostridium ghonii MW-DCG-HNCv-18 to the Docetaxel is 5×106-3.0×107:1 mg.
2. The pharmaceutical composition according to claim 1, wherein the ratio of the spores of Clostridium ghonii MW-DCG-HNCv-18 to the Docetaxel is 1.0×107-2.0×107:1 mg.
3. The pharmaceutical composition according to claim 2, wherein the ratio of the spores of Clostridium ghonii MW-DCG-HNCv-18 to the Docetaxel is 1.5×107:1 mg.
4. The pharmaceutical composition according to claim 1, wherein the spores are in a form of a spore freeze-dried powder for injection.
5. The pharmaceutical composition according to claim 4, wherein the spore freeze-dried powder for injection is mixed with a solvent for use, wherein the solvent is selected from a group consisting of Ringer's solution, saline with mass concentration of 0.9%, and phosphate buffer.
US15/525,046 2014-12-19 2015-07-08 Application of derivative of clostridium ghonii Active 2035-07-26 US10314809B2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN201410803072.XA CN104473973B (en) 2014-12-19 2014-12-19 The application of one strain Clostridium ghonii domestication strain
CN201410803072.X 2014-12-19
CN201410803072 2014-12-19
PCT/CN2015/083573 WO2016095503A1 (en) 2014-12-19 2015-07-08 Application of derivative of clostridium ghonii

Publications (2)

Publication Number Publication Date
US20170354633A1 US20170354633A1 (en) 2017-12-14
US10314809B2 true US10314809B2 (en) 2019-06-11

Family

ID=52748675

Family Applications (1)

Application Number Title Priority Date Filing Date
US15/525,046 Active 2035-07-26 US10314809B2 (en) 2014-12-19 2015-07-08 Application of derivative of clostridium ghonii

Country Status (5)

Country Link
US (1) US10314809B2 (en)
EP (1) EP3235501B1 (en)
CN (1) CN104473973B (en)
AU (1) AU2015366914B2 (en)
WO (1) WO2016095503A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103374538B (en) * 2012-04-27 2017-12-01 山东新创生物科技有限公司 Compositions comprising derived bacterial strains of Clostridium ghonii and methods of use thereof
CN104473973B (en) * 2014-12-19 2015-08-05 山东创新药物研发有限公司 The application of one strain Clostridium ghonii domestication strain
CN106265760B (en) * 2016-08-19 2018-05-25 山东新创生物科技有限公司 Clostridium ghonii tames application of the strain in radiotherapeutic sensitizer is prepared
CN106868024B (en) * 2017-04-01 2020-03-17 山东新创生物科技有限公司 Clostridium goeri specific PCR detection primer and method
US20240254434A1 (en) 2019-12-18 2024-08-01 Exomnis Biotech Bv Genetically modified clostridium strains and uses thereof
CN113855710B (en) * 2021-10-09 2024-02-20 施慧达药业集团(吉林)有限公司 Application of clostridium gossypii combined tumor angiogenesis inhibitor
CN115569193B (en) * 2021-10-09 2024-04-02 施慧达药业集团(吉林)有限公司 The application of Clostridium gordonii spores combined with pembrolizumab and the drug for treating colon cancer and the preparation method of Clostridium gordonii spores freeze-dried powder

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096909A (en) * 1994-10-28 2000-08-01 The Research Foundation Of State University Of New York Taxoid anti-tumor agents and pharmaceutical compositions thereof
WO2013159155A1 (en) * 2012-04-27 2013-10-31 Griffith University Oncolytic clostridium ghonii strains, and methods of production and use

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY34812A (en) * 2012-05-18 2013-12-31 Teva Pharma METHOD FOR TREATMENT OF LUNG CANCER OF NON-SMALL CELLS
CN103224898B (en) * 2013-03-05 2014-10-29 中国水产科学研究院黄海水产研究所 Marine bacillus and its polypeptide with antitumor activity
CN104161747A (en) * 2013-05-14 2014-11-26 赛诺菲（中国）投资有限公司 Application of docetaxel
CN104473973B (en) * 2014-12-19 2015-08-05 山东创新药物研发有限公司 The application of one strain Clostridium ghonii domestication strain

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096909A (en) * 1994-10-28 2000-08-01 The Research Foundation Of State University Of New York Taxoid anti-tumor agents and pharmaceutical compositions thereof
WO2013159155A1 (en) * 2012-04-27 2013-10-31 Griffith University Oncolytic clostridium ghonii strains, and methods of production and use

Also Published As

Publication number Publication date
EP3235501A1 (en) 2017-10-25
CN104473973A (en) 2015-04-01
US20170354633A1 (en) 2017-12-14
CN104473973B (en) 2015-08-05
EP3235501B1 (en) 2019-10-16
EP3235501A4 (en) 2018-08-15
AU2015366914A1 (en) 2017-06-08
WO2016095503A1 (en) 2016-06-23
AU2015366914B2 (en) 2021-03-25

Similar Documents

Publication Publication Date Title
US10314809B2 (en) Application of derivative of clostridium ghonii
Liu et al. Radiotherapy combined with an engineered Salmonella typhimurium inhibits tumor growth in a mouse model of colon cancer
Kim et al. Therapeutic effect of genetically modified human neural stem cells encoding cytosine deaminase on experimental glioma
RU2014147735A (en) ONCOLITIC STRAINS OF CLOSTRIDIUM GHONII, METHODS FOR PRODUCING AND USE
CN109414487A (en) Compositions and methods utilizing STAT1/3 inhibitors and oncolytic herpesviruses
CN107802653A (en) Inactivate application of the lactic acid bacteria in tumor disease medicine is prevented and treated
EP3448401B1 (en) Hsv vectors with enhanced replication in cancer cells
US20240115627A1 (en) Use of clostridium ghonii spore combined with pembrolizumab
CN103251600A (en) Antitumor application of 2-amino-4-(3'-cyano-4'-pyrrolidyl)phenylpyrimidine compound
CN106265760B (en) Clostridium ghonii tames application of the strain in radiotherapeutic sensitizer is prepared
CN109420167B (en) Combined medicine for treating tumor
CN112220917A (en) Combined medicine for treating malignant tumor
CN103202861A (en) Application of composition of clostridium butyricum and bifidobacterium dual live bacteria preparation and anticancer medicament in preparation of medicament for treating intestinal cancer
CN104739831A (en) Application of berberine in preparation of medicine for treating B-cell lymphoma
Girald et al. Toxicity and delivery methods for the linamarase/linamarin/glucose oxidase system, when used against human glioma tumors implanted in the brain of nude rats
Saini et al. Microbial mavericks: unleashing bacteria's tumor-seeking superpowers in the fight against cancer
Jazowiecka-Rakus et al. Antitumour activity of Salmonella typhimurium VNP20047 in B16 (F10) murine melanoma model.
US20200061133A1 (en) Use of recombinant oncolytic type ii herpes simplex virus in preparing medicines against lymphoma, esophageal cancer, breast cancer and pancreatic cancer
CN101974557A (en) Bifidobacterium pBES-tk recombinant vector for targeted therapy of solid tumor and application thereof
CN105193810B (en) 5 fluorouracil compositions and its application in antitumor injection is prepared
CN116870014B (en) Application of peimine in preparation of oncolytic virus antitumor synergist and composition containing peimine
CN102283845B (en) Application of ectoine and derivatives thereof in preparing tuberculosis treatment medicine
CN107737103A (en) A kind of intratumoral injection for treating rhabdomyosarcoma
Kumar et al. Recent progress in bacterial-mediated cancer therapy
CN117717600A (en) A proliferation agent that promotes the growth of Lactobacillus plantarum in tumors

Legal Events

Date Code Title Description
AS Assignment

Owner name: SHANDONG XINCHUANG BIOTECHNOLOGY CO., LTD., CHINA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:XING, LAITIAN;WANG, YONG;WEI, MINGQIAN;AND OTHERS;REEL/FRAME:042418/0513

Effective date: 20170426

STPP Information on status: patent application and granting procedure in general

Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS

STPP Information on status: patent application and granting procedure in general

Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT RECEIVED

STCF Information on status: patent grant

Free format text: PATENTED CASE

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YR, SMALL ENTITY (ORIGINAL EVENT CODE: M2551); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

Year of fee payment: 4

AS Assignment

Owner name: SHIHUIDA PHARMACEUTICAL GROUP (JILIN) CO., LTD., CHINA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SHANDONG XINCHUANG BIOLOGICAL TECHNOLOGY CO., LTD;REEL/FRAME:065180/0789

Effective date: 20231007